Lipocine (LPCN) Change in Accured Expenses (2011 - 2025)
Lipocine's (LPCN) quarterly Change in Accured Expenses came in at $63888.0 in Q3 2025, up 8.64% YoY from $58808.0 in Q3 2024, and down 3.74% on a QoQ basis from $66369.0 in Q2 2025.
Lipocine (LPCN) Change in Accured Expenses (2011 - 2025) Analysis & Trends
Lipocine (LPCN) has 15 years of Change in Accured Expenses data on file, last reported at $63888.0 in Q3 2025.
- Quarterly Change in Accured Expenses rose 8.64% year-over-year to $63888.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$542618.0 (down 457.05% YoY) and the FY2024 annual result came in at -$297246.0, down 311.19% from the prior year.
- Change in Accured Expenses slipped to $63888.0 in Q3 2025, from $66369.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $472012.0 in Q2 2024 to a low of -$554554.0 in Q4 2021.
- A 5-year average of -$47553.2 and a median of $55888.0 in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 645.79% — and 2024, when it slumped 917.74%.
- Tracing LPCN's Change in Accured Expenses over 5 years: stood at -$554554.0 in 2021, then soared by 135.5% to $196888.0 in 2022, then sank by 60.3% to $78173.0 in 2023, then slumped by 574.65% to -$371045.0 in 2024, then soared by 117.22% to $63888.0 in 2025.
- The last three Change in Accured Expenses figures came in at $63888.0 (Q3 2025), $66369.0 (Q2 2025), and -$301830.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 63,888.00 |
| Sep 30, 2025 | 63,888.00 |
| Jun 30, 2025 | 66,369.00 |
| Jun 30, 2025 | 66,369.00 |
| Mar 31, 2025 | -301,830.00 |
| Mar 31, 2025 | -301,830.00 |
| Dec 31, 2024 | -371,045.00 |
| Dec 31, 2024 | -371,045.00 |
| Sep 30, 2024 | 58,808.00 |
| Sep 30, 2024 | 58,808.00 |
| Jun 30, 2024 | 472,012.00 |
| Jun 30, 2024 | 472,012.00 |
| Mar 31, 2024 | -457,021.00 |
| Mar 31, 2024 | -457,021.00 |
| Dec 31, 2023 | 78,173.00 |
| Dec 31, 2023 | 78,173.00 |
| Sep 30, 2023 | -169,282.00 |
| Sep 30, 2023 | -169,282.00 |
| Jun 30, 2023 | 175,969.00 |
| Jun 30, 2023 | 175,969.00 |